Header Logo

Connection

Laurel Habel to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications Laurel Habel has written about Neoplasm Recurrence, Local.
Laurel Habel
Connection Strength
3.791
Neoplasm Recurrence, Local
  1. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat. 2018 02; 167(3):751-759.
    View in: PubMed
    Score: 0.515
  2. Reply to L. Cabel et al. J Clin Oncol. 2015 Jan 20; 33(3):292-3.
    View in: PubMed
    Score: 0.422
  3. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014 Jul 10; 32(20):2151-8.
    View in: PubMed
    Score: 0.406
  4. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
    View in: PubMed
    Score: 0.297
  5. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
    View in: PubMed
    Score: 0.297
  6. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst. 2004 Oct 06; 96(19):1467-72.
    View in: PubMed
    Score: 0.208
  7. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 1998 Aug; 7(8):689-96.
    View in: PubMed
    Score: 0.136
  8. Oncologist and organizational factors associated with variation in breast cancer multigene testing. Breast Cancer Res Treat. 2017 May; 163(1):167-176.
    View in: PubMed
    Score: 0.123
  9. Breast cancer multigene testing trends and impact on chemotherapy use. Am J Manag Care. 2016 05 01; 22(5):e153-60.
    View in: PubMed
    Score: 0.116
  10. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
    View in: PubMed
    Score: 0.115
  11. Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. Breast Cancer Res Treat. 2016 Feb; 155(3):541-9.
    View in: PubMed
    Score: 0.114
  12. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
    View in: PubMed
    Score: 0.113
  13. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
    View in: PubMed
    Score: 0.109
  14. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.108
  15. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ. Ann Surg Oncol. 2014 Nov; 21(12):3766-73.
    View in: PubMed
    Score: 0.101
  16. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):725-34.
    View in: PubMed
    Score: 0.099
  17. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
    View in: PubMed
    Score: 0.094
  18. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
    View in: PubMed
    Score: 0.087
  19. Multivitamin use and breast cancer outcomes in women with early-stage breast cancer: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2011 Nov; 130(1):195-205.
    View in: PubMed
    Score: 0.082
  20. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011 Sep; 129(2):549-56.
    View in: PubMed
    Score: 0.082
  21. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008 Jun; 109(3):573-9.
    View in: PubMed
    Score: 0.063
  22. Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women. J Am Coll Surg. 2023 07 01; 237(1):13-23.
    View in: PubMed
    Score: 0.047
  23. Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer Res. 2016 09 15; 76(18):5415-22.
    View in: PubMed
    Score: 0.030
  24. A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care. 2015 Apr; 53(4):380-5.
    View in: PubMed
    Score: 0.027

© 2024 Kaiser Permanente